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Abstract
Background: Providers wish to help patients with prescription costs but often lack drug cost information. We
examined whether giving providers formulary and drug cost information was associated with changes in their
diabetes patients’ drug costs and use. We conducted a longitudinal non-randomized evaluation of the web-based
Prescribing Guide (www.PrescribingGuide.com), a free resource available to Hawaii’s providers since 2006, which
summarizes the formularies and copayments of six health plans for drugs to treat 16 common health conditions.
All adult primary care physicians in Hawaii were offered the Prescribing Guide, and providers who enrolled received
a link to the website and regular hardcopy updates.
Methods: We analyzed prescription claims from a large health plan in Hawaii for 5,883 members with diabetes
from 2007 (baseline) to 2009 (follow-up). Patients were linked to 299 “main prescribing” providers, who on average,
accounted for >88 % of patients’ prescriptions and drug costs. We compared changes in drug costs and use for
“study” patients whose main provider enrolled to receive the Prescribing Guide, versus “control” patients whose
main provider did not enroll to receive the Prescribing Guide.
Results: In multivariate analyses controlling for provider specialty and clustering of patients by providers, both
patient groups experienced similar increases in number of prescriptions (+3.2 vs. +2.7 increase, p = 0.24), and days
supply of medications (+141 vs. +129 increase, p = 0.40) averaged across all drugs. Total and out-of-pocket drug
costs also increased for both control and study patients. However, control patients showed higher increases in
yearly total drug costs of $208 per patient (+$792 vs. +$584 increase, p = 0.02) and in 30-day supply costs (+$9.40
vs. +$6.08 increase, p = 0.03). Both groups experienced similar changes in yearly out-of-pocket costs (+$41 vs + $31
increase, p = 0.36) and per 30-day supply (−$0.23 vs. −$0.19 decrease, p = 0.996).
Conclusion: Giving formulary and drug cost information to providers was associated with lower increases in total
drug costs but not with lower out-of-pocket costs or greater medication use. Insurers and health information
technology businesses should continue to increase providers’ access to formulary and drug cost information at the
point of care.
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Background
Drug costs in the United States are rapidly rising and pro-
viders and patients are increasingly being asked to be aware
of medication cost when choosing treatments [1–3]. At the
same time, drug benefits have become more complex, with
increasing number of coverage tiers and different cost-
sharing requirements for each tier [4]. Therefore, providers’
and patients’ choice of which prescription drugs to use can
substantially affect patients’ out-of-pocket costs and even
medication adherence [5]. A study of 1.1 million insured
persons found that nearly half of patients could potentially
switch to lower cost but potentially effective drugs within
the same treatment class, decreasing total drug costs
between $389 and $452 per person and decreasing out-of-
pocket costs by $22 to $113 per person annually [6].
Currently, there is a need for better coordination to give
formulary and drug cost information to providers and pa-
tients at the point of care, such as in the office setting [7, 8].
Although providers are willing to help their patients by
prescribing less expensive drugs if appropriate and available
[9, 10], few providers accurately know such cost informa-
tion [10–12]. In our statewide survey of 247 adult primary
care physicians, nearly 100 % wanted to help patients with
drug costs, but 9 in 10 said that difficulty knowing cost
information prevented them from doing so [12]. This is
because providers often contract with multiple plans, up to
10 or more, and formularies and copayments for the same
drug may vary between plans as well as over time [13–15].
While health plans make formulary and drug cost informa-
tion available on their websites, such data may not be
linked to e-prescribing software [16]. In an industry survey
of 200 physicians, fewer than half had access to formularies
with their e-prescribing software, and fewer than one-third
had access to prior authorization or copayment information
[16]. Lack of easy access to formulary and drug cost infor-
mation for providers can result in their overlooking poten-
tially effective, lower cost drugs [6]. At the same time,
studies show that giving providers formulary decision
support can increase rates of prescribing drugs covered by
formularies and drugs with lower tier copayments [17–23].
We designed a community intervention to give
providers improved access to formulary and drug cost
information and measured changes in their patients’
drug costs and use. Since 2006, we have provided a free
web-based “Prescribing Guide” (PG) as a clinical
resource for Hawaii’s providers. The PG summarizes
formulary coverage and copayments from six health
plans for drugs used to treat 16 common health condi-
tions (e.g. asthma, diabetes, hypertension, etc.). For each
treatment class, the PG describes which drugs in that
class are covered, which drugs are brand-name or
generic, preferred or non-preferred, which require prior
authorizations, and the approximate copayments
charged by each plan (Fig. 1). The PG also highlights
which drugs in each class are widely covered at lower
copayments by all six plans, helping providers to learn
Fig. 1 Prescribing Guide – Diabetes. An excerpt from the Prescribing Guide showing formulary coverage and copayment information across six
health plans for insulin drugs used to treat diabetes
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quickly which drugs are less expensive and likely to
be covered for patients. Initially, a hardcopy of the
PG was mailed to all adult primary care providers in
the state identified from the Hawaii Medical Associa-
tion’s list of all licensed Hawaii physicians. Half of
providers (56 %) voluntarily signed up to continue
receiving quarterly PG updates. Shortly thereafter, a
web-based version www.PrescribingGuide.com was
also developed and the website link was sent to those
providers who enrolled, to use as needed with no
active reminders in their workflow. Providers were
surveyed annually to confirm that they still wished to
receive the PG and that they were still using this
resource. The one-year follow-up survey indicated
that the PG doubled the percentage of providers who
reported checking formularies (34 to 67 %) and knew
drug costs (11 to 29 %). The PG is inexpensive; main-
taining and updating the website for providers state-
wide now costs less than $5,000 per year.
In this study, we examined the changes in drug costs
and medication use for study patients whose providers
received the PG versus control patients whose
providers did not receive the PG. If giving better access
to formulary and drug cost information to providers
lowers their patients’ drug costs and increases medica-
tion use, this would support collaborations between in-
surers and the health information technology industry
to make formulary and drug cost information available
at the point of care.
Methods
Patients
We partnered with a large health plan in Hawaii that
covers ~70 % of the state’s privately insured residents
[24]. Claims and enrollment data were used to
include patients with diabetes in 2007 and 2009 who
were enrolled for >320 days in each year and filled
one or more oral diabetes prescriptions. Individuals
with diabetes were chosen since the great majority of
persons with diabetes require medications to reach
glycemic control (85 %), are on multiple medications,
and are vulnerable to drug costs [25–29]. Between 14
and 49 % of persons with diabetes report medication
nonadherence due to cost [26–29] The health plan
flagged patients as having diabetes if they had two or
more outpatient visits for diabetes based on icd-9
codes (International Statistical Classification of
Diseases and Related Health Problems) or one visit
for diabetes and one or more prescriptions for a dia-
betes medication. Medicaid members were excluded
since they have $0 prescription copayments. Medicare
members were excluded since Part D plans were not
included in the PG. During the study period, the
health plan made no major changes to their drug
benefit design and most commercial members paid
tiered dollar copayments for preferred generic and
brand-name drugs.
Study assignment
Each patient was linked to their “main” prescriber,
defined as the provider who wrote the greatest number
of prescriptions for them in that year. Providers were
required to be a general internist, family physician,
general practitioner, endocrinologist, or cardiologist and
the main prescriber for ten or more patients each year.
Patients were eligible if they were linked to the same
main prescribing provider in 2007 and 2009. These
patients were assigned to the “study” group if their main
prescriber enrolled to receive the PG or to the “control”
group if their main prescriber did not enroll to receive
the PG.
Medication use and drug costs
For each patient, we calculated the changes from 2007
to 2009 in medication use (number of prescriptions,
total days supply of medications), and total drug costs
(paid by plan and patient) and patients’ out-of-pocket
costs per year and per 30-day supply of medications.
These were calculated for all drugs (including non-
diabetes medications), and then separately for brand-
name versus generic drugs.
Analyses
We conducted multivariate analyses using SAS 9.4 Proc
Mixed to determine whether control patients and study
patients were different at baseline (2007) and follow-up
(2009) in terms of medication use and drug costs [30]. To
examine the impact of the PG, we tested for differences in
the changes in medication use and drug costs over time
for control patients vs. study patients. The Proc Mixed
procedure was chosen because it is fairly robust, does not
rely on the dependent variables (e.g. medication use, drug
costs) being normally distributed, and can account for
patient clustering by provider (i.e. correlation in outcomes
between patients with the same main prescribing
provider) [30]. For all analyses, the main predictor was
whether the patient’s provider received the PG (study
patients) or not (control patients) and we controlled for
provider specialty. We also conducted sensitivity analyses
restricting analyses to primary care providers and to drug
claims from the main prescribing providers, which did not
change the main study findings.
Results
A total of 6,433 patients ages 21–64 with diabetes were
enrolled for ≥320 days and filled at least one oral
diabetes prescription in both 2007 and 2009. These
patients were linked to 327 “main prescribing” providers
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who prescribed the highest number of prescriptions for
them in either 2007 or 2009 (Fig. 2). Of these patients,
5,883 (91 %) were linked to the same “main prescribing”
provider in both years (299 providers) and included in
our final analyses. Linkage was tight, with main prescrib-
ing providers accounting for the vast majority of their
patients’ number of prescriptions (88 %), days supply of
medications (90 %), total drug costs (89 %), and out-of-
pocket costs (88 %). Providers were mainly general
internists (69 %), family physicians (17 %), and endocri-
nologists (8 %), followed by general practitioners (5 %)
and cardiologists (1 %).
The 5,883 patients represented $42.7 million in total
drug costs, $5.96 million in out-of-pocket drug costs,
433,945 prescriptions, and 15.3 million days supply of
medications for the two years.
At baseline, both control and study patients started with
similar yearly overall medication use, total drug costs, and
out-of-pocket costs based on all drugs. Both groups began
with comparable number of prescriptions per year (35.5 vs.
35.4, p = 0.48), days supply of medications (1233 vs. 1233,
p = 0.34), yearly total drug costs ($3340 vs. $3216, p = 0.74),
and yearly out-of-pocket costs ($503 vs. $473, p = 0.39)
(Table 1). However, at baseline, control patients used less of
generic drugs in terms of number of generic prescriptions
(19.9 vs. 21.1, p = 0.02) and days supply of generic drugs
(675 vs 727, p = .003). Thus, control patients started with
higher total drug costs per 30-day supply ($81 vs. $77, p =
0.03) as well as higher out-of-pocket costs per 30-day sup-
ply ($12 vs. $11, p = 0.01) than did study patients. Standard
deviations for Basline medication use and cost in 2007
(Table 1) are available in Additional file 1: Appendix 1.
At follow-up in 2009, control patients continued to
have both higher total drug costs per 30-day supply
($90 vs. $83, p = 0.003) as well as higher out-of-pocket
costs per 30-day supply ($12 vs. $11, p = .01). Again,
this was due to control patients’ trend of using less of
generic drugs in terms of number of generic prescrip-
tions (22.0 vs. 23.0, p = 0.08) and days supply of generic
drugs (768 vs. 815, p = 0.02) (Table 2). However, control
patients now also used more brand-name drugs in
terms of yearly number of brand-name prescriptions
(16.6 vs. 15.0, p = 0.04) and days supply of brand-name
prescriptions (606 vs. 547, p = 0.049), compared to study
patients. Standard deviations for Follow-up medication
use and cost in 2009 (Table 2) are available in Additional
file 1: Appendix 2.
In evaluating the impact of the PG by examining the
differences in changes over time in medication use and
drug costs for control versus study patients, both groups
experienced comparable increases in overall medication
use, brand-name drug use, and generic drug use. Both
groups showed similar increases in number of prescrip-
tions (+3.2 vs. +2.7 increase, p = 0.24), and in days
supply of medications per year (+141 vs. +129 increase,
p = 0.40) (Table 3). Standard deviations for Change in
medication use and cost from Baseline to Follow-up year
(Table 3) are available in Additional file 1: Appendix 3.
However with respect to cost, increases in yearly total
drug cost were $208 higher per control patient (+$792
vs. +$584 increase, p = 0.02) than per study patient
(Table 3). This higher increase in yearly total drug costs
occurred both for generic drugs (+$2 increase vs −$34
decrease, p = 0.053) and for brand-name drugs (+$790
vs + $619 increase, p = 0.07), both of which approached
statistical significance. The higher increase in total drug
cost occurred although control patients did not have
greater increases in number of prescriptions for brand-
name drugs (+1.1 vs. +0.8 increase, p = 0.32) and generic
drugs (+2.1 vs. +1.9 increase, p = 0.43), compared to
study patients. Rather for the control group, the cost of
generic drugs per 30-day supply tended to drop slower
(−$3.42 vs. −$5.11, p = 0.065) and the cost of brand-
name drugs per 30-day supply tended to rise faster over
time (+$30 vs. +$25 increase, p = 0.20) than it did for
study patients.
With respect to copayments, there were no significant
differences between control and study patients in
changes in yearly out-of-pocket costs (+$41 vs + $31
increase, p = 0.36) or out-of-pocket costs per 30-day
supply (−$0.23 vs. −$0.19 decrease, p = 0.996).
Fig. 2 Patient eligibility and linkage to main prescribing physician. A
flowchart showing the link between eligible plan enrollees with
diabetes and their main prescribing physician who prescribed the
highest number of prescriptions for them in a given year
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Discussion
We found that improving providers’ access to formulary
and drug cost information was associated with lower
increases in yearly total drug costs averaging $208 per
patient, but not lower out-of-pocket costs or increased
medication use. Since out-of-pocket costs were not
affected, this represents primarily savings to health plans
rather than direct savings for patients. However, there
may be indirect benefits to patients if lower total drug
costs for insurers lead to fewer premium increases. Our
study used a simple website to provide such drug cost
information, but our results support findings from the
limited number of larger scale studies examining the
integration of formularies and drug costs into e-
prescribing [18–21]. Fischer’s study of e-prescribing with
formulary support for 1.5 million patients estimated
total drug cost savings of $845,000 per 100,000 patients
assuming a 20 % uptake among their providers [18].
McMullin’s study of 38 primary care providers with half
receiving e-prescribing with clinical decision support
(including preferred drug options) estimated total drug
cost savings at $1.07 per member per month (~$1.2 mil-
lion per 100,000 patients) [19, 20]. Zuker’s study of 647
providers and e-prescribing with formulary support esti-
mated total drug cost savings of 4 % [21]. These studies
did not report whether giving formulary information re-
duced out-of-pocket costs or increased medication use.
Our study did not find such an impact. However, Pev-
nick’s study of 297 providers and e-prescribing with for-
mulary support estimated modest decreases in out-of-
pocket costs when focusing on two drug classes:
angiotensin-receptor blockers and inhaled steroids, al-
though there was no increase in their medication use
(adherence) [17]. Overall, our study supports the hy-
pothesis that giving providers formulary and drug cost
information can potentially lower total drug costs.
We found that both groups had similar increases in
their use of brand-name and generic drugs (number of
prescriptions, days supply of medication). This indicates
that the savings in total drug costs came surprisingly, not
Table 1 BASELINE medication use and cost in 2007a
All drugs Generic drugs Brand-name drugs
Baseline year (2007) Control Study p-value Control Study p-value Control Study p-value
Medication use
Number of prescriptions 35.5 35.4 0.48 19.9 21.1 0.02* 15.6 14.3 0.13
Total days supply 1233 1233 0.34 675 727 0.003* 558 506 0.11
Total drug cost, $
Per year 3340 3216 0.74 860 925 0.02* 2480 2291 0.29
Per 30-day supply 81 77 0.03* 40 40 0.51 129 127 0.55
Out-of-pocket cost, $
Per year 503 473 0.40 112 120 0.005* 391 353 0.15
Per 30-day supply 12 11 0.01* 5 5 0.11 21 20 0.22
*Statistically significant at p < 0.05
aMultivariate analyses SAS Proc Mixed 9.4 comparing Control (n = 3061) vs. Study patients (n = 2822), controlling for clustering by provider and controlling for
provider specialty. Standard deviations for Baseline medication use and cost in 2007 are available in Additional file 1: Appendix 1.
Table 2 FOLLOW-UP medication use and cost in 2009a
All drugs Generic drugs Brand-name drugs
Follow-up Year (2009) Control Study p-value Control Study p-value Control Study p-value
Medication use
Number of prescriptions 38.6 38.0 0.97 22.0 23.0 0.08 16.6 15.0 0.04*
Total days supply 1374 1362 0.67 768 815 0.02* 606 547 0.049*
Total drug cost, $
Per year 4131 3800 0.11 861 890 0.29 3270 2910 0.049*
Per 30-day supply 90 83 0.003* 36 34 0.02* 159 152 0.08
Out-of-pocket cost, $
Per year 545 504 0.18 127 134 0.03* 418 370 0.07
Per 30-day supply 12 11 0.01* 6 5 0.02* 21 20 0.03*
*Statistically significant at p < 0.05
aMultivariate analyses SAS Proc Mixed 9.4 comparing Control (n = 3061) vs. Study patients (n = 2822), controlling for clustering by provider and controlling for
provider specialty. Standard deviations for Follow-up medication use and cost in 2009 are available in Additional file 1: Appendix 2.
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from greater use of generic versus brand-name drugs (e.g.
switching from brand-name to generic drugs or new pre-
scriptions being written for generic rather than brand-
name drugs). Also, changes in out-of-pocket costs were
similar, meaning the total drug cost savings did not come
from choosing formulary versus non-formulary drugs, or
from choosing lower tiered drugs which would have led to
lower out-of-pocket costs. This is surprising since prior
studies show that giving formulary and drug cost informa-
tion to providers increases their prescribing of generic and
formulary preferred drugs [17–23]. In our study, the lower
increase in yearly total drug costs were in part due to the
study group experiencing slower increases in total drug
costs per 30-day supply for their brand-name and generic
drugs. This is unexpected since the PG gave providers for-
mulary information and out-of-pocket costs, and not total
drug costs. The PG may have had this effect because we
intentionally highlighted “widely covered” drugs (bolded
with yellow highlights) so that providers could easily learn
which drugs were likely to be covered and low cost for
their patients regardless of the drug plan. Prescribing
these widely covered drugs could decrease total drug
costs if health plans preferentially cover these drugs
because they are less expensive for insurers to purchase.
Thus when giving providers formulary and drug cost
information, consideration should be given to highlight
which drugs are widely covered by all plans at lower cost.
Similar to prior studies, ours was not a randomized con-
trol trial [17–23]. We also had access only to prescription
claims data and could not control for important patient-
level characteristics such as age, gender, and co-morbidities
which can impact drug costs and adherence [31]. However,
prior to the PG intervention, both study and control
patients started with similar overall medication use (total
number of prescriptions, days supply of medication, and
days supply per prescription) and overall drug costs (yearly
total drug costs and yearly out-of-pocket costs) although
study patients did start with higher generic drug use. Also,
over half of all the adult primary care providers in Hawaii
who were offered the PG voluntarily signed up to continue
receiving updates, indicating the substantial interest from
providers to have better access to formulary and drug infor-
mation even in low-technology form. Thus, our findings
should lend support to greater efforts to give formulary
and drug cost information to providers and patients. This
is especially important since the current trend is for
drug benefits to become increasingly more complex with
growing number of coverage tiers and copayments [4, 5].
Our PG had the advantage of easy development (over a
few months), being free to providers, pharmacists, and
office staff, and requiring no proprietary software or user
licenses for use. Pharmacy students now maintain the PG
website for the entire state at minimal cost by checking
formularies each month. However, on a national level, a
more practical approach would be to increase the linkage
of formularies and drug costs to e-prescribing [32–34].
With the Affordable Care Act, providers face a 1.5 %
payment reduction in reimbursements unless they adopt
e-prescribing [35]. In 2014 e-prescribing increased to 70 %
of providers, up from 7 % in 2008 [36]. Greater linkage of
formulary and copayment data with e-prescribing software
would be invaluable to giving providers and patients
access to drug cost information at the point of care.
A major limitation of our study was that it was not
randomized, and our analyses could not include patient
characteristics which can affect medication use such as
age, race, sex, income which were not available from
prescription claims [31]. We were able to control for
provider specialty, but did not have access to other
provider characteristics, such as number of years in
practice, which may affect knowledge of drug costs. The
study focused on patients with diabetes with at least one
Table 3 CHANGE in medication use and cost from BASELINE to FOLLOW-UP yeara
All drugs Generic drugs Brand-name drugs
Change from 2007 to 2009 Control Study p-value Control Study p-value Control Study p-value
Medication use
Number of prescriptions 3.2 2.7 0.24 2.1 1.9 0.43 1.1 0.8 0.32
Total days supply 141 129 0.40 93 89 0.63 48 41 0.45
Total drug cost, $
Per year 792 584 0.02* 2 −34 0.053 790 619 0.07
Per 30-day supply 9.40 6.08 0.03* −3.42 −5.11 0.065 30 25 0.20
Out-of-pocket cost, $
Per year 41 31 0.36 15 14 0.44 26 17 0.44
Per 30-day supply −0.23 −0.19 0.996 0.30 0.13 0.19 0.32 −0.23 0.27
*Statistically significant at p < 0.05
aMultivariate analyses SAS Proc Mixed 9.4 comparing Control (n = 3061) vs. Study patients (n = 2822), controlling for clustering by provider and controlling for
provider specialty. Standard deviations for Change in medication use and cost from Baseline to Follow-up year are available in Additional file 1: Appendix 3.
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oral medication, although all drugs were include in
analyses, and the PG may have less impact on drug costs
for healthier patients or those who are on fewer medica-
tions. Lastly, unlike e-prescribing, we were unable to
measure PG use directly. However, we conducted annual
follow-up written questionnaires and telephone calls to
confirm through providers’ self-report that they were
still using the PG.
Conclusion
Giving providers formulary and drug cost information at
the point of care was associated with lower increases in
annual total drug costs without significant impact on
out-of-pocket costs or medication use. On a national
level, insurers such as Medicare, Medicaid, and commer-
cial health plans should continue to partner with health
information technology businesses to improve providers’
and patients’ access to formulary and drug cost informa-
tion at the point of care.
Additional file
Additional file 1: Appendix 1. BASELINE medication use and cost in
2007 – Means and standard deviations. Baseline medication use and cost
of patients’ prescription drugs in 2007. Appendix 1 is the same as Table 1
in the manuscript, but includes the standard deviations. Appendix 2.
FOLLOW-UP medication use and cost in 2009 – Means and standard
deviations. Follow-up medication use and cost of patients’ prescription
drugs in 2009. Appendix 2 is the same as Table 2 in the manuscript, but
includes the standard deviations. Appendix 3. CHANGE in medication use
and cost from BASELINE to FOLLOW-UP year – Means and standard
deviations. Change in medication use and cost of patients’ prescription
drugs from 2007 to 2009. Appendix 3 is the same as Table 3 in the
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